eli lilly news glp-1 is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating FDA just approved orforglipron (Foundayo),

Across much of the South and Midwest, the combination of high obesity prevalence, lower wages, and limited insurance coverage creates what could be described as GLP-1 deserts regions where access is constrained not just by price, but by insurance exclusions and state-level policy decisions

It was found that more patients in the LIR group than the placebo group maintained their weight loss by 5%, which indicated that LIR 3.0 mg/d is expected to improve the maintenance of weight loss (93)

Zepbound (tirzepatide): Similar to Mounjaro, the half life is about 5 days

MEDVis pricing starts attractively, but the ongoing cost of tirzepatide injections typically increases to around $499 per month , placing it on the higher end of the market

Research suggests you need to take more than 1 gram per day for more than 8 weeks.) That said, problems with the limited research means that we dont know how effective it really is

doi: 10.1097/01.mlr.0000182534.19832.83 [DOI] [PubMed] [Google Scholar] 112.Gasparini A